Wegovy and Mounjaro work fast, but cost and sustainability pose problems
GLP-1 medications help people lose weight fast, but cost and support gaps create barriers.
Matt Winchester lost 12 kilograms in 12 weeks on Wegovy, a medication originally designed for type 2 diabetes. GLP-1 drugs reduce appetite and help people without diabetes lose weight too.
Winchester is a nurse who struggled privately while counselling patients about healthy living. The medication gave him a chance.
Meg Burridge tried Mounjaro but stopped when it cost too much. Once she quit, her hunger came back.
She was unsure about what to do next. Her experience raises a harder question.
What happens when people stop taking these drugs? Health psychologist Bronwyn Wood warns that GLP-1 use is complex.
It often lacks proper support. Some people get prescribed these medications without full information.
They don't get access to diet advice or mental health support alongside treatment. Wood says the growing use of these drugs reflects a wider obsession with thinness in our culture.
- 12 kilograms in 12 weeks
- Weight lost in time
- GLP-1 agonists
- Medication type
- Type 2 diabetes treatment
- Original purpose
Why it mattersWhen people stop these medications due to cost or side effects, the weight typically returns and they often lack a plan to manage it.
AustraliaThese drugs are becoming mainstream in Australia, but access depends on cost and ongoing affordability. Long-term outcomes and psychological support remain gaps in how they are prescribed.
✓ Claims checked against the source and corrected before publish. checked 4 d ago
